Cash is good until 2016 they have the bridge they needed.
ABT will put a PR out but not until launch is my guess. IMHO that is when we see this move.
R/S is NOT a done deal and if this gets over a buck after ABT PR and they have time on Aspire deal
they will be set. I hope we get positive news from NASDAQ soon as that will give us a nice up tic as well.
My feeling is a lot of what if questions were laid out in the CC this stock is way over sold.
I plan on buying back in today with the 75% I took off a while back. I like the fact we know have an
idea of the direction this is going...
Check it out. Looks like they are preparing for the automated US launch.
Much more informative and detailed. On the US site a direct link to Abbott for the automated test.
On the European site direct links to both Abbott and Biomerieux for the
automated test. It's about time.
Waiting to hear about the date for the annual shareholders meeting, about
the letter from Nasdaq granting extension and most of all from Abbott.
Looks like weak hands have folded and some shaking of the tree.
Once the dust settles ( possibly tomorrow), back to the basics. Analysts have BGMD making 8 million by Dec 2015? A 194% sales growth by Dec 2015 according to what yahoo is showing.
Just thought I would throw that it in the mix.
I just came back from an acupuncture session and now I'm feeling relaxed.
Otherwise, I could be line for those cardio tests real quick:))
Actually that is not a valid reason why the sales are poor. Different countries provide medical care differently.
It's all up to Abbott to carry the torch for sales revenue for BGMD and that in itself, carries "risk'. Plain and simple. They have a great partner......now they need to show revenues for the future. How much and how long does it take for BGMD to recognize revenues? How will the new Galectin-3 automated platform be received? What are the royalties for BGMD?
Look at PUMA today. Another rocket ship that is about to crash and burn. Over 200 bucks PPS with even completing phase 2 trials. Crazy! Shorts should have a field day.
stuggling?...they even did not fight :)))...look at their q1 2014 CC: "We expect that by the end of the second quarter, our U.S. field sales organization will be approximately twice the size that it was in the second quarter of 2013"
q2 2014 CC "we are in the process of shifting our focus to begin setting the stage for the anticipated U.S. market introduction of galectin-3 automated testing by our partners Abbott" and they started to cut their sales force on anticipation of something...the gave up and let ABT do all job for them...and bankruptcy they actually almost approached is artificial: they cut their sales force without even trying to aggressively penetrate the market, they did not dilture enough money and also their largest customer decrease number of orders (still did not find explanation for this...they did not even try to explain)...everything tells that they clean up path for ABT in their future market launch
You don't see it irrational that a struggling Biotech that averts BK is bad news as reflected in PPS activity? I beg to differ.
You raise a valid point but you can't compare the European market with the American market in terms of heart disease rates. The Southern States alone have the worst rate of obesity and heart disease of all. Most European countries top list of least heart disease. France is number 1 despite their high in dairy diet. Go figure.
regarding the EU launch..i believe ABT was responsible for that....but in US BG generated 4 million a year right at the beginning when the test wasn't automated
that is the kind of BOD responsibility I'm referring too…
FDA is slow, product development is slow, every month money goes away and when they could say something to help PPS stability… no comment
Very good thanks to the board
partially agree with you about uncertainty..but if look closer to any company you can find uncertainty everywhere..SNSS drop like a stone from $8-$1 just because they could not meet their primary endpoint (correct me if i wrong) and market anticipated before that everything is just fine...i can find bunch of companies that reached 200-300 million market cap just taking about coming partnership or FDA approval but nothing happen and after failure they still have market cap of 150 mill of so
Those other Companies still have the POTENTIAL of a future. BGMD has realized their "future" - Its dead in the water as there simply is no interest in the Company or their test (Re: European launch = NO REVENUE)
Sentiment: Strong Sell
Why would anyone expect growth from U.S. Launch? There IS NO INTEREST in this test - whether manual or automated!! .... Maybe why no one has SWOOPED IN to STEAL this great value of a Company before Abbott does ............ Hope you are not holding your breath (or worse - holding shares). BGMD IS A DUD.
Sentiment: Strong Sell
Agree with you...really don't understand how market valuate BIO companies...some companies like ACHN have 1 billion market cap but has no partner or FDA approval..market is completely irrational...other example APPY has even higher market cap then BGMD when they apply to 510k and had no partner nor sales